| アブストラクト | AIMS: To assess the association between the use of sodium-glucose cotransporter-2 (SGLT2i) and cardiovascular outcomes and death as a function of obesity among patients with type 2 diabetes. METHODS: This new-user, active-comparator cohort study used U.K.'s Clinical Practice Research Datalink linked to Hospital Episodes Statistics repository and Office for National Statistics. The cohort included 34,128 new-users of SGLT2i matched 1:1 to 34,128 new-users of dipeptidyl peptidase-4 inhibitors (DPP-4i) on body mass index and propensity score. Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of major adverse cardiovascular events (MACE), overall and in body mass index (BMI) categories (</=24.9 kg/m(2), 25.0-29.9 kg/m(2), 30.0-39.9 kg/m(2), >/=40 kg/m(2)). Secondary outcomes included all-cause mortality and hospitalization for heart failure. RESULTS: SGLT2i were associated with a decreased risk of MACE (HR: 0.78, 95 %CI: 0.69-0.88) compared to DPP-4i. This decreased risk was most pronounced among obese and severely obese patients (HR: 0.77, 95 %CI: 0.66-0.91; HR: 0.67, 95% CI: 0.49-0.91, respectively) but not among overweight patients (HR: 0.94, 95 %CI: 0.73-1.22). Similar patterns were observed for cardiovascular mortality, all-cause mortality, and heart failure. CONCLUSION: Compared with DPP-4i, the cardioprotective effect associated with SGLT2i is stronger among patients with higher BMI. |
|---|
| 組織名 | Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine,;Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.;Electronic address: ksuissa@bwh.harvard.edu.;Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital,;Montreal, Canada; Department of Epidemiology, Biostatistics, and Occupational;Health, McGill University, Montreal, Canada; Department of Medicine, McGill;University, Montreal, Canada; Institute of Clinical Pharmacology and Toxicology,;Charite - Universitatsmedizin Berlin, Berlin, Germany.;Montreal, Canada.;Health, McGill University, Montreal, Canada; Gerald Bronfman Department of;Oncology, McGill University, Montreal, Canada. |
|---|
